DRKS00028829
Completed
Phase 3
COVID-19: Reducing Symptoms and Hospitalization rates by use of Azelastine Nasal spray in patients suffering from COVID-19 in Early stages - CHANCE
RSAPHARM Arzneimittel GmbH0 sites272 target enrollmentApril 13, 2022
ConditionsTreatment of COVID-19 patients
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Treatment of COVID-19 patients
- Sponsor
- RSAPHARM Arzneimittel GmbH
- Enrollment
- 272
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Legally competent patients who are personally capable of giving informed consent and to sign and date the Consent Form prior to any trial related activity,
- •\- Patients that exhibit COVID\-19\-related symptoms, of which a) at least two are scored at baseline with 2” or 3” OR b) at least six are scored at baseline at 1” or higher, but which have not yet lasted longer than 2 days.
- •\- Patients aged from 18 to 80 years, whether vaccinated to SARS\-CoV\-2 or not.
- •Unvaccinated patients can be included only if they do not fulfil the following risk factors for a severe course of SARS\-CoV\-2 infection: Diabetes, obesity (BMI \> 25\), chronic lung disease (including asthma), chronic kidney disorder, current smoking, immunosuppressive disease or immunosuppressive therapy, heart disease, hypertension, sickle cell disease, neurodevelopmental disorders, active cancer, medical technological dependence, or age 60 years or older, regardless of comorbidities. The patient’s family physician will take the decision on the inclusion of unvaccinated patients, considering the patient’s anamnesis and concomitant medication.
- •\- Having the diagnosis of SARS\-CoV\-2 infection documented by a positive Rapid Antigen Test or positive PCR testing. Positive Rapid Antigen Test results must be confirmed through another Rapid Antigen test performed in presence of the investigator during the inclusion visit. Patients will be included in the study based on eligibility criteria and after signing the informed consent. The patient will undergo all study related procedures on the same day (baseline RT\-PCR test using nasal swabs, physical examination, vital signs, concomitant medications etc) including study drug administration. The decision of continuing the patient further in the study will be decided on the results of RT\-PCR (patients exhibiting baseline Ct\- 25 will be continued, patients exhibiting baseline Ct\-values \> 25 will be discontinued from the study). In case of baseline Ct\-values \> 25, the drug will be immediately withdrawn, and patients will be discontinued from the study.
Exclusion Criteria
- •\- Patients requiring hospitalization at the time of enrolment,
- •\- Simultaneous participation in other clinical trials or previous participation within 30 days before inclusion,
- •\- Being in any relationship or dependence with the Sponsor, CRO and/or Investigator,
- •\- Inability to understand instructions/study documents,
- •\- Inability to administer the nasal spray
- •\- Specific vulnerable patients: subjects who are detained or committed to institutions by law court or by legal authorities, such as psychiatric wards, prisons or other state institutions
- •\- Any additional antihistamine therapy from Day 1 of the trial to Day 16 (locally or systemically applied), any antihistamine therapy 7 days prior to enrolment
- •\- Any concurrent nasalia including nasal lavage fluids
- •\- Any concurrent anti\-COVID therapy (including off\-label use) such as (inhalative) corticosteroids or anti\-viral and immune\-modulatory active substances, for example Sotrovimab, Molnupiravir, Paxlovid (Nirmatrelvir und Ritonavir).
- •\- Unvaccinated patients who are eligible for therapy with already approved COVID\-19 medicinal products
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 2
COVID-19 Prevention of worsening of symptoms in asymptomatic to mild patients by combined use of kakkonto and hochuekkito:Exploratory open-label randomized controlled trialCOVID-19JPRN-jRCTs041200072Ogawa Keiko100
Not yet recruiting
Not Applicable
ower morbidity and mortality in COVID-19 patients admitted in a dedicated COVID Hospital of Odisha - A Radiological perspectiveHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: R99- Ill-defined and unknown cause of mortalityCTRI/2020/08/027247Dr Roopak Dubey
Active, not recruiting
Not Applicable
Symptom reduction in hospitalized patients suffering from symptomatic non-erosive or erosive gastroesophageal reflux disease treated with pantoprazole 20 or 40 mg o.d. for 7 days - PROFISymptomatic non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD)MedDRA version: 8.1Level: LLTClassification code 10017885Term: Gastrooesophageal reflux diseaseEUCTR2005-004856-11-DEALTANA Pharma AG350
Active, not recruiting
Phase 1
Treatment with Omega-3 polyunsaturated fatty acids in COVID-19 patients.A single-blind, randomized, placebo-controlled feasibility study.SARS-COV-2 InfectionMedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2020-002293-28-SEKarolinska University Hospital40
Active, not recruiting
Phase 1
Treatment of non-severe confirmed cases of coronavirus and treatment of their contacts as preventioSARS-CoV-2 Respiratory Viral InfectionMedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: PTClassification code 10070255Term: Coronavirus test positiveSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2020-001031-27-ESFUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA3,040